Products

ViBone Moldable, provided by Aziyo Biologics, is a next-generation viable cell bone matrix optimized to protect and preserve the health of native bone cells.

ALLOB will be applied by a single injection up to 4 days post-reduction surgery in patients with fresh tibial fractures at risk for delayed or non-union.

Expanded coverage includes treatment of symptomatic full-thickness cartilage defects in the patella and multiple cartilage defects in the knee.

This demineralized bone fiber form is designed for minimal access delivery into expandable cages, revisions and other surgical applications.

In 1H21, the company will launch FusePure Demineralized Bone Matrix, Strips and Cubes, and FuseTrilogy Viable Bone Matrix.

The company has completed recruitment and treated all patients in its Phase III study with the viscosupplement, JTA-004, in patients with knee osteoarthritis.

Over 25,000 of Theracell's licensed demineralized bone fiber products have been delivered by the company's licensee partners.

The human extracellular matrix is slated to enter a Phase 1/2 Trial for knee cartilage regeneration in 1Q21.

FIBRI-CELL with Osteo-Spin offers a novel approach to enhance traditional bone graft substitutes for orthopedic fusion.

During its 10 years' partnership with LAS Brasil, Graftys achieved the milestone of 10,000 units of GRAFTYS HBS sold in Brazil.